Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ornstein

Showing results (221-230 of 233) with videos related to

Pageof 24
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 13, 2006
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivoBrianne Weiss, Andrew Alt, Ann Marie Ogden, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Synthesis and structure-activity relationships of novel dipeptides and reduced dipeptides as ligands for melanocortin subtype-4 receptorQing Shi, Paul L Ornstein, Karin Briner, et al.
Journal of Medicinal Chemistry|September 20, 2002
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraineSandra A Filla, Mark A Winter, Kirk W Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 27, 2019
Modulation of TARP <i>γ</i>8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic PainKelly L Knopp, Rosa Maria A Simmons, Wenhong Guo, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2013
GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain modelsJose A Martinez-Perez, Smriti Iyengar, Harlan E Shannon, et al.
Journal of Medicinal Chemistry|January 23, 2004
Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptorTimothy I Richardson, Paul L Ornstein, Karin Briner, et al.
Nature Medicine|November 8, 2016
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanismAkihiko S Kato, Kevin D Burris, Kevin M Gardinier, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacyJose A Martinez-Perez, Smriti Iyengar, Harlan E Shannon, et al.
Journal of Medicinal Chemistry|June 25, 2005
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of painEsteban Dominguez, Smriti Iyengar, Harlan E Shannon, et al.
Pageof 24

Showing results (221-230 of 233) with videos related to

Sort By:
Pageof 24
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 13, 2006
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivoBrianne Weiss, Andrew Alt, Ann Marie Ogden, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Synthesis and structure-activity relationships of novel dipeptides and reduced dipeptides as ligands for melanocortin subtype-4 receptorQing Shi, Paul L Ornstein, Karin Briner, et al.
Journal of Medicinal Chemistry|September 20, 2002
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraineSandra A Filla, Mark A Winter, Kirk W Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 27, 2019
Modulation of TARP <i>γ</i>8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic PainKelly L Knopp, Rosa Maria A Simmons, Wenhong Guo, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2013
GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain modelsJose A Martinez-Perez, Smriti Iyengar, Harlan E Shannon, et al.
Journal of Medicinal Chemistry|January 23, 2004
Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptorTimothy I Richardson, Paul L Ornstein, Karin Briner, et al.
Nature Medicine|November 8, 2016
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanismAkihiko S Kato, Kevin D Burris, Kevin M Gardinier, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacyJose A Martinez-Perez, Smriti Iyengar, Harlan E Shannon, et al.
Journal of Medicinal Chemistry|June 25, 2005
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of painEsteban Dominguez, Smriti Iyengar, Harlan E Shannon, et al.
Pageof 24